Oral Crizotinib induced severe esophageal ulcer with stenosis: a case
report and literature review
Abstract
Crizotinib is an oral [anaplastic lymphoma
kinase](https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase)
and [c-ros oncogene
1](https://en.wikipedia.org/wiki/C-ros_oncogene_1) inhibitor, which
is approved by the Food and Drug Administration for the treatment of
metastatic non-small cell lung cancer (NSCLC). The 2011 Clinical trials
demonstrated excellent treatment response, survival, and few side
effects. We report a case of severe ulcerative oesophagitis with
stenosis that was not reported in the 2011 Clinical trials and earlier
studies.